HCmed Innovations Co., Ltd. (6934) is pleased to announce that it has recently become a public company in Taiwan. The contract development and manufacturing organization (CDMO) that focuses on drug-nebulizer combination product development plans to register as an Emerging Stock company in 2023.
Founded in 2014, HCmed Innovations Co., Ltd. (HCmed) focuses on the development of drug-nebulizer combination products for inhalation therapy. As a full-service CDMO, HCmed provides a wide range of services with two customizable nebulizer platforms and aerosol characterization services to support the development process, mass production of nebulizers, and post-market surveillance (PMS).
As one of the few companies in the world that specializes in the development of drug-nebulizer combination products, HCmed supports global pharmaceutical partners with its high-quality nebulizer technology and customization capabilities. As HCmed continuously collaborates with various global partners, these projects are expected to contribute to HCmed’s operations and revenue.
